Lipogems International is a technology company.
Lipogems International has raised $15.0M across 2 funding rounds.
Lipogems International has raised $15.0M in total across 2 funding rounds.
Lipogems International is an Italian biotech multinational company headquartered in Milan, with a U.S. presence in Norcross, Georgia, specializing in regenerative medicine through its proprietary Lipogems® system. This FDA-cleared medical device harvests, processes, and deploys a patient's own adipose (fat) tissue—known as microfat—via a minimally invasive, enzyme-free method to support tissue repair and healing, serving orthopedic surgeons, general surgeons, and plastic surgeons treating conditions like knee osteoarthritis, joint damage, and wounds.[1][2][3][4] It addresses the problem of limited non-surgical options for patients unsuitable for invasive procedures, enabling faster recovery and lifestyle restoration; over 60,000 procedures have been performed globally across 29 countries, backed by 140+ independent peer-reviewed publications, including 5-year follow-up data in orthopedics.[5][6]
The company targets patients exhausted by conservative therapies, offering a compliant, point-of-care alternative used in 250+ U.S. orthopedic centers and military sites, with strong growth evidenced by a €12.5M ($13.2M) funding round in 2022 to fuel FDA IDE studies for knee osteoarthritis.[2][5][6]
Founded as a privately held medical device company in Italy, Lipogems International Spa emerged to pioneer adipose-derived regenerative solutions, drawing on historical uses of fat tissue for healing—dating back to World War I wound treatment—and modern research into its stem cell potential.[1][4] The core Lipogems® system achieved U.S. 510(k) clearance in 2014 as the first device for harvesting, concentrating, and transferring autologous adipose tissue under FDA minimal manipulation guidelines for homologous use.[2][3][4]
Key milestones include global distribution starting in 27 (now 29) countries, accumulation of 125+ (now 140+) peer-reviewed studies by 2022, and expansion via 2022 growth capital from LIFTT SpA—a healthcare VC firm led by serial entrepreneur Stefano Buono—to advance clinical trials.[5][6] Leadership figures like Giorgio Ninzoli (President, Lipogems International) and Carl Llewellyn (President, Lipogems USA) have driven its evolution from a reparative medicine innovator to a leader in orthopedics and beyond.[5]
Lipogems rides the explosive growth in regenerative medicine, particularly adipose-derived therapies, amid rising demand for biologics that leverage the body's healing potential over pharmaceuticals or implants—fueled by aging populations, osteoarthritis prevalence (affecting millions), and post-pandemic shifts toward minimally invasive outpatient care.[4][5][6] Timing aligns with stringent FDA regulations on human cellular/tissue products (HCT/Ps under 21 CFR 1271), where Lipogems' 2014 clearance positioned it as a compliant pioneer ahead of enforcement curves.[2][4]
Market forces like escalating orthopedic procedure costs, surgeon preferences for evidence-based biologics, and military validation favor its expansion; it influences the ecosystem by partnering with institutions for research, standardizing microfat as a mainstream tool, and enabling continuum-of-care models that keep patients out of major surgery.[1][5] This democratizes access to next-gen adipose tech, challenging traditional interventions in a $50B+ global regen med market.
Lipogems is primed for acceleration, with ongoing FDA IDE studies in knee OA poised to unlock disease-specific indications, potentially boosting U.S. adoption beyond general use and mirroring its global traction.[6] Trends like AI-driven personalization in regen med, expanded wound care applications, and payer reimbursement for biologics will shape its path, alongside further independent trials building on 140+ publications.
Its influence may evolve from niche innovator to category leader, influencing standards in orthobiologics and inspiring enzyme-free platforms; as funding and data compound, expect deeper integration into value-based care, tying back to its mission of harnessing "the power of fat" for natural, patient-centric healing.[1][5][7]
Lipogems International has raised $15.0M in total across 2 funding rounds.
Lipogems International's investors include LIFTT.
Lipogems International has raised $15.0M across 2 funding rounds. Most recently, it raised $13.0M Series A in December 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2022 | $13.0M Series A | LIFTT | |
| Jul 1, 2022 | $2.0M Seed | LIFTT |